You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com
and Hepatitis.com Coverage of the
61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010)
October 29 - November 2, 2010, Boston, MA
Do IL28B Gene Variations Affect Liver Disease Progression in People with Hepatitis C?
Single nucleotide polymorphisms, or SNPs, are substitutions of a single nucleotide building block at a specific position in a DNA chain. A number of SNPs -- most often 12979860 -- on chromosome 19 near the IL28B gene have been linked to hepatitis C outcomes. The IL28B gene encodes interferon lambda, or interleukin 28; interferons produced by the body are key to the immune response against HCV, and injected interferon therapy strengthens this natural response.
carries 2 copies of every gene, one from each parent. The IL28B rs12979860
SNP has 2 variations, or alleles, known as "C" and "T."
Hepatitis C patients with the homozygous or matching C/C pattern (2
copies of the "C" allele) are most likely to spontaneously
clear HCV and have the best treatment outcomes. People with the homozygous
T/T pattern (2 "T" alleles) have the least favorable response,
while those with the heterozygous or mixed C/T pattern (1 copy of each
variation) fall in between. Other implicated IL28B SNPs have different
specific letter combinations, but the principle is the same.
Davide Bitetto from the University of Udine in Italy and colleagues looked at the link between the IL28B rs12979860 SNP and fibrosis progression in 548 people with HCV infection and 428 healthy blood donor; just over half of the hepatitis C patients were men and the median age was 56 years.
Participants were categorized according to liver disease severity. A total of 349 had chronic hepatitis and had never received antiviral treatment; in this group, 235 had mild liver fibrosis (Ishak stage F2 or lower) and 114 had advanced fibrosis (stage F3-F4). In addition, there were 199 patients with liver cirrhosis, 51 of whom also had hepatocellular carcinoma (HCC).
Looking at rs12979860 SNP frequency among the hepatitis C patients, 32% had the protective C/C gene pattern, 54% had the C/T pattern, and 14% had the unfavorable T/T pattern. Among healthy control subjects, the corresponding proportions were 47%, 42%, and 11%.
The likelihood of having the T/T pattern rose as liver disease worsened. Only 9% of patients with mild chronic hepatitis carried the T/T pattern, rising to 17% of those with more advanced liver disease, and 24% of those with cirrhosis and HCC -- a statistically significant trend.
IL-28B rs12979860 polymorphism "appears to influence the natural history of chronic hepatitis C," the researchers concluded. "Carrying the T/T genotype favors the evolution of the disease until the development of HCC."
No Fibrosis Difference
In contrast, a smaller Spanish study failed to find a similar association. Jose Del Campo from Hospital de Valme in Seville and colleagues looked at 129 hepatitis C patients with HCV genotype 1 patients who were treated with pegylated interferon/ribavirin for 48 weeks.
saw no difference in SNP pattern distribution according to extent of
liver disease. About one-third (30%) of patients with absent-to-mild
(METAVIR stage F0-F1) fibrosis carried the protective C/C pattern, compared
with 41% of those with moderate (F2) fibrosis, and 36% of those with
advanced (F3-F4) liver disease -- not a significant difference.
Thompson and fellow investigators with the IDEAL
study presented findings from 2 analyses looking at IL28B polymorphisms
and liver disease severity. The Phase 3b IDEAL trial compared pegylated
interferon alfa-2a (Pegasys) vs pegylated interferon alfa-2b (PegIntron),
both with weight-adjusted ribavirin, in more that 3000 previously untreated
HCV genotype 1 patients.
Here, too, the researchers saw no relationship between IL28B pattern and advanced (METAVIR stage F3-F4) fibrosis. This was true overall and also when patients were categorized by race/ethnicity (white, black, or Hispanic) -- done because blacks are less likely than whites to carry the protective C/C pattern and respond more poorly to interferon.
In the second analysis, however, the researchers did see a link between rs12979860 pattern and alanine aminotransferase (ALT) levels and necro-inflammatory activity. People with the protective C/C gene pattern had higher pre-treatment ALT and were more likely to have moderate-to-severe (METAVIR stage A2-A3) necro-inflammatory activity.
Numerous prior studies have shown that people with higher ALT and greater necro-inflammatory activity -- an indicator of active liver inflammation -- are more likely to achieve SVR. The IDEAL researchers suggested that this association might be explained by IL28B variations.
Another pair of studies presented at the conference showed that IL28B variations also may help predict outcomes after liver transplantation.
D Bitetto, C Fabris, E Fornasiere, and others. C>T polymorphism affects the evolution of chronic hepatitis C. 61st Annual Meeting of the American Association for the Study of Liver Diseases AASLD 2010). Boston, October 29-November 2, 2010. Abstract 230.
JA Del Campo, M Maraver Zamora, R. Ramirez-Lorca, and other. IL28B polymorphism predicts sustained virological response in hepatitis C but is not associated with fibrosis or viral load. 61st Annual Meeting of the American Association for the Study of Liver Diseases AASLD 2010). Boston, October 29-November 2, 2010. Abstract 892.
AJ Thompson, J Clark, J Fellay, and others. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the IDEAL study. 61st Annual Meeting of the American Association for the Study of Liver Diseases AASLD 2010). Boston, October 29-November 2, 2010. Abstract 229.
AJ Thompson, PJ Clark, M Zhu, and others. Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study. 61st Annual Meeting of the American Association for the Study of Liver Diseases AASLD 2010). Boston, October 29-November 2, 2010. Abstract 1893.